Liquid biopsy is a non-invasive diagnostic technique that involves analyzing circulating tumor cells (CTCs) or cell-free DNA (cfDNA) from a patient's blood to detect the presence and characteristics of cancer.
Liquid biopsy addresses the limitations of traditional tissue biopsies by providing a non-invasive alternative that can be performed more frequently, leading to better patient outcomes through early detection and personalized treatment plans.
The process typically involves collecting a small volume of blood, which is then processed using various techniques such as filtration, magnetic sorting, or microfluidics. The isolated CTCs or cfDNA are then analyzed for specific genetic markers or mutations associated with cancer. This allows for the identification and monitoring of cancer progression in real-time.
The manufacturing process involves developing and optimizing techniques for blood sample collection, processing, and analysis. This includes the design and production of microfluidic devices or filtration systems, as well as the development of assays for detecting specific genetic markers.
The build process starts with the selection of appropriate technologies for sample preparation and analysis. This is followed by rigorous testing to ensure accuracy and reliability. The process also involves creating databases of known cancer mutations and developing algorithms for interpreting the results.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.